Clinical Trial Update: Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 safety study evaluating gene-modified donor T-cells after partially mismatched stem cell transplantation in patients with leukemia and related condi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Lymphoma
• Myelodysplastic Syndromes

Drugs mentioned

• Bellicum Pharmaceuticals gene-modified donor T-cells

Snippet

Sponsor: Bellicum Pharmaceuticals | Conditions: Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING